» Articles » PMID: 14726503

Mortality After Cure of Testicular Seminoma

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2004 Jan 17
PMID 14726503
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the incidence of potentially treatment-related mortality in long-term survivors of testicular seminoma treated by orchiectomy and radiation therapy (XRT).

Patients And Methods: From all 477 men with stage I or II testicular seminoma treated at The University of Texas M.D. Anderson Cancer Center (Houston, TX) with post-orchiectomy megavoltage XRT between 1951 and 1999, 453 never sustained relapse of their disease. Long-term survival for these 453 men was evaluated with the person-years method to determine the standardized mortality ratio (SMR). SMRs were calculated for all causes of death, cardiac deaths, and cancer deaths using standard US data for males.

Results: After a median follow-up of 13.3 years, the 10-, 20-, 30-, and 40-year actuarial survival rates were 93%, 79%, 59%, and 26%, respectively. The all-cause SMR over the entire observation interval was 1.59 (99% CI, 1.21 to 2.04). The SMR was not excessive for the first 15 years of follow-up: SMR, 1.30 (95% CI, 0.93 to 1.77); but beyond 15 years the SMR was 1.85 (99% CI, 1.30 to 2.55). The overall cardiac-specific SMR was 1.61 (95% CI, 1.21 to 2.24). The cardiac SMR was significantly elevated only beyond 15 years (P <.01). The overall cancer-specific SMR was 1.91 (99% CI, 1.14 to 2.98). The cancer SMR was also significant only after 15 years of follow-up (P <.01). An increased mortality was evident in patients treated with and without mediastinal XRT.

Conclusion: Long-term survivors of seminoma treated with post-orchiectomy XRT are at significant excess risk of death as a result of cardiac disease or second cancer. Management strategies that minimize these risks but maintain the excellent hitherto observed cure rates need to be actively pursued.

Citing Articles

Development of Fournier's gangrene after chemotherapy for the recurrence of testicular cancer despite the absence of anorectal lesions: A case report.

Nonaka K, Kawase K, Takagi K, Takatsu Y, Maniwa K, Takao C Medicine (Baltimore). 2024; 103(30):e38688.

PMID: 39058861 PMC: 11272336. DOI: 10.1097/MD.0000000000038688.


Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience.

Thor A, Negaard H, Bergdahl A, Almas B, Larsen S, Lundgren P Eur Urol Open Sci. 2024; 65:13-19.

PMID: 38966804 PMC: 11222926. DOI: 10.1016/j.euros.2024.05.006.


Competing risk nomogram predicting cause-specific mortality in older patients with testicular germ cell tumors.

Wu X, Zhou M, Lyu J, Chen L Front Med (Lausanne). 2024; 11:1327485.

PMID: 38695022 PMC: 11061386. DOI: 10.3389/fmed.2024.1327485.


Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer.

McClintock G, Goolam A, Perera D, Downey R, Leslie S, Grimison P Asian J Urol. 2024; 11(1):121-127.

PMID: 38312811 PMC: 10837656. DOI: 10.1016/j.ajur.2022.03.010.


Advances in radiation therapy for testicular seminoma.

Rosen D, Tan A, Pursley J, Kamran S World J Urol. 2023; 41(12):3895-3903.

PMID: 37979002 DOI: 10.1007/s00345-023-04674-8.